TABLE 1.
Reported Trials of Immunotherapy in Cervical Cancer (Original table)
| Author/yr | Regimen | |||||||
|---|---|---|---|---|---|---|---|---|
| Prior Systemic Therapy | n | PD-L1 | ORR% (CI) (95%tile CI) | PFS months (95%tile CI) | OS months (95%tile CI) | |||
| ADXS11 | Basu [14] | ADXS11-001 | 0 | 56 | NA | 17.1% (8.1-32.7) | 6.1 (5.9-9.4) | 8.3 (5.8-10.5) |
| ADXS11-001 + cisplatin | 54 | NA | 14.7% (6.4-30.1) | 6.4 (4.2-8.9) | 8.8 (7.4-13.3) | |||
| GOG-0265 | Huh [20] | ADXS11-001 | 1-3 | 50 | NA | 3.7% (0.1-18.3) | 3.1 (2.8-3.7) | 6.2 (4.4-12.3) |
| KEYNOTE-028 | Frenel [22] | Pembrolizumab 10 mg/kg | 1-3 | 24 | + | 17% (5-37) | 2.0 (2.0-3.0) | 11.0 (4-15) |
| KEYNOTE-158 | Chung [23] | Pembrolizumab 200 mg | 0-5 | 98 | +/− | 12.2% (6.5-20.4) | 2.1 (2.0-2.1) | 9.4 (7.7-13.1) |
| 84 | + | 14.6% (7.8-24.2) | 2.1 (2.1-2.3) | 11.0 (9.1-14.1) | ||||
| GY002 | Santin [26] | Nivolumab 3 mg/kg | 1+ | 25 | +/− | 4.0% (0.4-22.9) | 3.5 (1.9-5.1) | 14.5 (8.3-26.8) |
| Ipilimumab | Lheureux [28] | Ipilimumab 10mg/kg | 1-3 | 42 | +/− | 2.7% (0.5-14.9) | 2.5 (2.1-3.2) | 8.5 (3.6-NR) |
| CheckMate 358 | Naumann [27] | Nivo Only | 1-2 | +/− | 26.3% (9.1-51.2) | 5.1mo (1.9-9.1) | 21.9 (15.1-NR) | |
| Naumann [41] | Ipi 1 + Nivo 3 | 0 | 19 | +/− | 31.6% (12.6-56.6) | 13.8 (2.1-NR) | NR (17.4-NR) | |
| 1-2 | 26 | +/− | 23.1% (9.0-43.6) | 3.6 (1.9-5.1) | 10.3 (7.9-15.2) | |||
| Ipi 3 + Nivo 1 | 0 | 24 | +/− | 45.8% (25.6-67.2) | 8.5 (3.7-NR) | NR (13.9-NR) | ||
| 1-2 | 22 | +/− | 36% (17.2-59.3) | 5.8 (3.5-17.2) | 25.4 (17.5-NR) |
NR- Not Reached
Ipi = Ipilimumab
Nivo = Nivolumab